I went back to my three former FDA Investigator colleagues for a second conversation.
The first time I asked them how they found deficiencies. This time I asked them where.
I spent 14 years as an FDA Investigator myself. Then 13 years as a Quality executive on the industry side. Then 6 years auditing from the outside. I have seen every one of these areas from every angle — as the Investigator writing the 483, as the Quality Director receiving it, and as the auditor warning companies before FDA arrived.
What my former colleagues described was not random. Across different facilities, different product types, different states — the same five areas produced the most critical findings. Every time.
Before I name them, one thing worth stating clearly: those websites that collect 483 observations and try to help companies profile Investigators based on citation patterns are not useful. Most inspections involve more than one Investigator. You don’t know which observation belongs to which person. You’re profiling a ghost.
What my colleagues described is different. This is institutional knowledge from career Investigators — the areas where deficiencies were most likely to indicate a quality system that had lost genuine control.
The ones that drove Warning Letters. The ones that resulted in OAI classifications. The ones that ended careers and shut down production lines.
And that’s not hyperbole. In one inspection, the Quality Director abruptly resigned on the second day.
Why This Intelligence Is Different
The most commonly cited 483 observations are publicly available. FDA publishes the data. What is not publicly available is what a career Investigator actually looks for within each of those systems — the specific patterns, the specific data requests, the specific interview questions that reveal whether a system is functioning or being managed for appearances.
That is what my three former colleagues shared. And it is what is in the paid edition of The Investigator’s Lens — including CFR citations for each area, the specific techniques Investigators use to evaluate each system, and the preparation actions that neutralize each vulnerability before FDA identifies it.
Read the full article here: https://open.substack.com/pub/devaughnedwards/p/former-fda-investigators-revealed?r=7sflcx&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true
DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.
Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831
FD-AID | FDA Inspection Readiness | Former FDA Investigator 